DOCSLIB.ORG

Georgia Core and Cancer Collaboration in Georgia

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Georgia Core and Cancer Collaboration in Georgia 11/27/2017 GEORGIA CORE AND CANCER COLLABORATION IN GEORGIA GATRA CONFERENCE MACON, GA NOVEMBER 6, 2017 Nancy M. Paris, MSHA, FACHE President Georgia Center for Oncology Research and Education M M M M M M M M M M Mm M M M M M *American Cancer Society, Cancer Facts & Figures 2017 .org M M M M M M M M M M Mm M M M M M M *American Cancer Society, Cancer Facts & Figures 2017 1 11/27/2017 National Progress Against Cancer • Life expectancy is increasing for cancer patients • 3 years since 1980 • Cancer death rates are down • Rates fell an average of 2.1% per year from 2002 – 2004; twice the decline of the previous 5 years • 20% decline in cancer deaths over last two decades • Five-year survival is rising • Approximately 75% • New medicines and practices advance treatment *Innovation.org Increase in colorectal cancer in young adults • There is an increase in colorectal cancer seen in young adults (less than 50 years) • Incidence rates have increased faster for rectal cancer than colon cancer. • Could likely be attributed to “Complex relationship between colorectal cancer and obesity, unhealthy diet, and lack of physical activity.” - Dr. Otis Brawley (ACS). • Due to increase in left-sided tumors, particularly in the rectum According to Rebecca L. Siegel, Ahmedin Jemal and Elizabeth M. Ward (2009) In an article published in American Association for Cancer Research • Others say cause of increased incidence is unknown Cancer in Georgia • Cancer is the second leading cause of death in Georgia, accounting for almost a quarter of all deaths. • Lung, colorectal, breast, and prostate cancer account for more than half of all cancer deaths in Georgia. • Minority and medically underserved Georgians experience a disproportionate cancer burden. • Cancer care is excessively costly for employers and the state of Georgia. 2 11/27/2017 Growth of Cancer Related Investments in Georgia Increased Philanthropic Investments Numerous cancer centers bear the names of corporations and donors demonstrating greater private contributions Growth in National Cancer Institute Funding • 2000 $14 mil; • up by 100% in 2005 to $28 mil; • up by 30% in 2010 to $38 mil; • up by 25% in 2015 to $47 mil Escalation in federal funding and academic research Georgia ranks 21st in federal funding; academic cancer research centers at Augusta University, Clark Atlanta, Emory, Georgia Tech, Mercer, Morehouse and the University of Georgia Georgia CORE was created in 2003 with funding from the State of Georgia’s “Tobacco Settlement” Georgia CORE is a public-private partnership that works collaboratively with oncologists, cancer centers, public health and academic institutions to provide higher quality, better organized, more cost-effective, patient- centered care. Supported by: • Georgia Department of Public Health • Georgia Department of Community Health • Georgia Society of Clinical Oncology (GASCO) • Georgia Research Alliance • Government and Foundation Grants • Private Contributions and Sponsorships • Industry Contracts Board of Directors Andrew W. Pippas, MD Chairman Frederick M. Schnell, MD, FACP Chief Medical Officer Nancy M. Paris, MSHA, FACHE President Guilherme Cantuaria, MD, PhD Roland Matthews, MD Teresa A. Coleman, MD, FACP Steven McCune, MD, PhD Walter J. Curran, Jr., MD, FACR Charles H. Nash, III, MD Lynn Durham, MPA Petros Nikolinakos, MD Sharad Ghamande, MD Patti Owen, MN John W. Henson, IV, MD, MBA, FACHE Jayanthi Srinivasiah, MD Harvey James Hamrick, MD, MPH Jose Tongol, MD Anand P. Jillella, MD H. A. Zaren, MD 3 11/27/2017 Research Network • Archbold Medical Center • Nancy N. and J.C. Lewis Cancer & Research • Atlanta Cancer Care Pavilion at St. Joseph’s/Candler • CTCA at Southeastern Regional Medical • Northeast Georgia Health System and Center Medical Center • Central Georgia Cancer Care • Northside Hospital Cancer Institute • Curtis and Elizabeth Anderson Cancer • Northwest Georgia Oncology Centers Institute at Memorial University Medical • Peyton Anderson Cancer Center/Navicent Center Health • DeKalb Medical • Phoebe Putney Memorial Hospital • Georgia Cancer Center for Excellence at • Piedmont Cancer Institute Grady Memorial Hospital • Southern Regional Medical Center • Georgia Cancer Center, Augusta University • South Georgia Medical Center, Pearlman • Gwinnett Medical Center Cancer Center • Harbin Clinic • University Cancer and Blood Center • John B. Amos Cancer Center, Columbus • Wellstar Health System Regional Health • Winship Cancer Institute of Emory • Morehouse School of Medicine University Georgia CORE Model Research Accelerate cancer research & expand evidence‐based care Knowledge Transfer Navigation & Facilitate quality Outreach cancer care and Connect patients & exchange of best and survivors to doctors, promising practices Higher quality, better trials, care & organized, more resources cost‐effective, patient centered cancer care Education Awareness Promote evidence‐ Champion Georgia‐ based guidelines for based care & risk reduction, resources prevention & screening Strategic Direction & Statewide Initiatives Research Network NCI Community GeorgiaCancer Oncology Info.org Research Program Georgia’s Cancer Plan Cancer 2014‐2019 Genetic Survivorship Services Connection Cancer Patient Breast Cancer Navigators of License Tag GA 4 11/27/2017 Georgia Cancer Plan 2014 -2019 1.Cancer Risk Reduction: Tobacco and Obesity 2.Vaccination for Human Papilloma Virus 3.Breast and Cervical Cancer Screening 4.Colorectal Cancer Screening 5.Lung Cancer Screening 6.Quality Cancer Diagnosis and Treatment 7.Access to Palliative Care and Survivorship 8.Patient Case Management and Care Coordination Members of the GC3 Consortium GeorgiaCORE.org 5 11/27/2017 What Can Collaboration Accomplish? 1000 900 800 700 600 500 400 300 200 100 0 2009 2010 2011 2012 2013 2014 2015 2016 Adult Trials (97%) Pediatric Trials (27%) Total Trials (900) * www.GeorgiaCancerInfo.org Some variance between Adult and Pediatric trial totals as some count 18+ Adult, while others consider 21+ Adult. Trials, Doctors and Cancer Centers on GeorgiaCancerInfo.org Searchable Online Cancer Information Partnership with NCI Certified by Health on the Net • 605 Clinical Trials • 836 Oncologists • 397 Cancer Treatment Sites • National Treatment Standards and Guidelines • Community Resources throughout Georgia • Cancer Survivorship Connection • Statewide Initiatives • 39,464 Unique Users in 2016 6 11/27/2017 Cancer Trials in Georgia (GeorgiaCancerInfo.org) • 53 Cancer types by which to search for trials • 72 Breast cancer trials, 36 Brain cancer trials, 14 Colorectal cancer trials • 584 Adult trials in Georgia • 201 Pediatric Trials Number of Trials by Phases in Georgia 269, 44% 250 200 170, 28% 160, 26% Trials 150 of 100 Number 50 6, 1% 0 IIIIIIIV Phase Proliferation of Clinical Trials and Accredited Centers Eleven-fold increase in cancer clinical trials (from 82 to 900) Research hubs in greater Atlanta counties – Fulton, DeKalb, Gwinnett and Cobb; and in Albany, Athens, Columbus, Dublin, Gainesville, Macon, Thomasville, Valdosta, Rome and Savannah 700 100 90 600 80 70 500 60 50 400 40 30 300 20 10 200 0 100 0 Atlanta Decatur Lawrenceville Marietta Trials within 25 miles Oncologists within 25 miles *www.GeorgiaCancerInfo.org NCI Community Oncology Research Program (NCORP) NCI funded 2 Georgia-based consortiums for 5 years; 34 funded nationally. • Minority NCORP • Augusta University • DeKalb Medical Center • Georgia Southern University • Morehouse School of Medicine • Phoebe Putney Memorial Hospital • Georgia NCORP • Northside Hospital • St. Joseph's/Candler • Georgia CORE with Harbin Clinic, John B. Amos Cancer Center, Peyton Anderson Cancer Center at Navicent Health and Northeast Georgia Medical Center 7 11/27/2017 Georgia NCORP The primary goal is to increase access and accrual to cancer research for Georgians at risk for or with a diagnosis of cancer in their own communities, with a targeted focus on the underserved. Partners Cancer Incidence Rate Northside Hospital Cancer Institute St. Joseph’s/Candler Lewis Cancer & Research Pavilion Georgia Center for Oncology Research and Education Network Members Harbin Clinic John B. Amos Cancer Center at Columbus Regional Health Peyton Anderson Cancer Center, Navicent Health Cancer Services at Northeast Georgia Medical Center Georgia NCORP Highlights • 103 rostered physicians, 52 accruing • 76 NCI clinical trials open • 41% of accruals to high priority/precision medicine trials • 23.4% racial/ethnic minority accruals • Investigators and research managers active in leadership • Recognition as a High Performing NCORP by NCI • In top quartile of NCORPs for achieving stated goals • Among top 4 accruers nationally to NRG Oncology Survivorship Resources on GeorgiaCancerInfo.org/Survivorship 8 11/27/2017 What is Needed to Improve Quality of Life for Survivors? Survivor Financial Support TEAM CARE Employment Support Insurance Support Healthy Lifestyle RESEARCH Attitude FAITH INFORMATION/ Programs Survivorship COMPASSION Plan LISTEN Encourage EDUCATION Support Groups Resources Mentorship TIME FOLLOW‐UP CARE Honesty Patience Transportation Communication Counseling Cancer Survivor Needs Physical Emotional Sleep & Fatigue Depression Pain Spiritual Anxiety Spiritual Neuropathy Managing Stress Weight Gain Fear of Recurrence Sexuality Quality New Normal of Life Practical Spiritual Financial & Money Loss of Faith Work related Religious Support Health Insurance Managing Household Hope Return to responsibilities End of Life Thoughts Georgia’s Cancer Survivor Voices From the
Load more

Recommended publications
  • 6-27-12 Otis Brawly Final 24 Min 47
    (Music) Mark Masselli: This is Conversations on Health Care. I am Mark Masselli. Margaret Flinter: And I am Margaret Flinter. Mark Masselli: Well Margaret, here we are, two years after the passage of The Patient Protection and Affordable Care Act and it feels like we are standing on the precipice as apparently the Supreme Court will be making an announcement on this Thursday. Margaret Flinter: After years of such hard work to transform health care in America, now the fate of the Affordable Care Act at least lies in the hands of those justices. Mark Masselli: Well, I am an optimistic pessimist, hope for the best and fear the worst. We have a conservative leaning court and we still don’t know what they may deem as unconstitutional. Margaret Flinter: A majority seem to think that the individual mandate requiring all Americans to buy health insurance or face paying a fine is the most vulnerable part of the law. Mark Masselli: Margaret, it's just hard to believe with all the great minds working on fixing health care, insuring the 35 million uninsured, protecting Americans with preexisting conditions from being denied coverage that all that hard work could be in jeopardy. We should note here that a lot of money was spent attempting to sway the court of public opinion. It's estimated that conservatives spent about $235 million specifically attacking the Affordable Care Act. Margaret Flinter: You know, a lot of the positive changes that were brought about by health reform law, have already been implemented although we tend not to hear so much about it.
    [Show full text]
  • Town Hall Meeting August 19, 2020 — 12:00PM – 2:00PM Central Time
    Town Hall Meeting August 19, 2020 — 12:00PM – 2:00PM Central Time Short Tribal Musical Bill Ward • President Song Community Health Advocate and Motivational Speaker Native Research Network Inc. Prostate Program Advisory Council For Spirit of Eagles Mayo Clinic - Rochester, MN. Partnership (NACP) Native American Cancer Prevention University of Arizona & Northern Arizona University Community Action Committee Outreach - Member Opening Remarks Pat Matthews-Juarez, PhD • Chair Thelma Hurd, MD, MPH • Chair-Elect Introduction of Lovell A. Jones, PhD • Co-Founder and Past Chair Speaker Speaker “Cancer Prevention and Control: Current State of Cancer Care for Racial/Ethnic and Vulnerable Populations” Otis Brawley, MD Professor of Oncology 39th Bloomberg Distinguished Professor Johns Hopkins University School of Medicine Introduction of Armin Weinberg, PhD • Co-Founder and Co-Chair Speakers Speaker “Comprehensive Cancer Control National Partners” Nikki Hayes, MPH Chief, Comprehensive Caner Control Branch, Division of Cancer Prevention and Control National Center for Chronic Disease Prevention and Control Centers for Disease Control and Prevention Speaker Leslie S. Given, BA, MPA Strategic Health Concepts Closing Pat Matthews-Juarez, PhD • Chair Town Hall Meeting Biographies Speaker “Cancer Prevention and Control: Current State of Cancer Care for Racial/Ethnic and Vulnerable Populations” Otis Brawley, MD Professor of Oncology 39th Bloomberg Distinguished Professor Johns Hopkins University School of Medicine Otis Brawley is professor of oncology at the Johns Hopkins University School of Medicine and 39th Bloomberg Distinguished Professor at Johns Hopkins. Dr. Brawley leads a broad interdisciplinary research effort of cancer health disparities at the Johns Hopkins Bloomberg School of Public Health and the Johns Hopkins Kimmel Cancer Center, working to close racial, economic and social disparities in the prevention, detection and treatment of cancer in the United States and worldwide.
    [Show full text]
  • Increasing Racial Diversity in Cancer Research and Cancer Care Donita C
    Published OnlineFirst August 18, 2020; DOI: 10.1158/2159-8290.CD-20-1193 VIEWS SCIENCE IN SOCIETY The Race toward Equity: Increasing Racial Diversity in Cancer Research and Cancer Care Donita C. Brady 1 , 2 and Ashani T. Weeraratna 3 , 4 Summary: Cancer research and cancer care require deliberate attention to racial diversity. Here we comment on the ongoing issues of diversity and racism in cancer research. INTRODUCTION Transformative, intentional initiatives at our institutions and funding agencies aimed at the retention and recruitment The horrifi c murders of George Floyd, Breonna Taylor, of Black trainees and professors within the cancer research and countless others have had a profound effect on the col- enterprise are therefore critical to creating preeminent aca- lective conscience of our society, prompting us to reexamine demic research environments ( 1 ). Furthermore, many cancers our own bias and survey for race-based discrimination to such as breast, lung, and prostate cancers disproportionately begin to acknowledge and combat the existing racism within affect people of color, and those health disparities need to our own ivory towers. This introspection has opened the be addressed. To do this, community outreach is critical to eyes of many to the overt and implicit biases Black scien- increase screening and encourage participation in clinical tists face. Essential discussions stemming from this new trials and laboratory-based studies. However, that cannot be awakening have been uncomfortable and eye-opening, and done without building trust between underrepresented com- have resulted in many important conversations on social munities and the medical institutions that have historically media and in person on our campuses.
    [Show full text]
  • Improving Cancer Diagnosis and Care: Patient Access to Oncologic
    Improving Cancer Diagnosis and Care: Patient Access to Oncologic Imaging and Pathology Expertise and Technologies: A Workshop FEBRUARY 12 – 13, 2018 Keck Center of the National Academies 500 Fifth Street, NW AGENDA Washington, DC Room 100 February 12, 2018 7:30 am Registration and Breakfast 8:00 am Welcome from the National Cancer Policy Forum Sharyl Nass Director, National Cancer Policy Forum Overview of the Workshop Hedvig Hricak, Memorial Sloan Kettering Cancer Center Planning Committee Chair 8:15 am Session 1: Patient Access to Diagnostic Expertise in Oncology Moderator: Christopher Cogle, University of Florida Challenges to Ensuring that Patients Have Access to Diagnostic Expertise to Inform the Best Possible Cancer Care Otis Brawley, American Cancer Society Oncologic Imaging: Gaps and Challenges to High-Quality Cancer Diagnosis in Clinical Practice Hedvig Hricak, Memorial Sloan Kettering Cancer Center Oncologic Pathology: Gaps and Challenges to High-Quality Cancer Diagnosis in Clinical Practice Michael Cohen, Wake Forest School of Medicine Panel Discussion: Vision for the Future: Ensuring Access to Diagnostic Expertise in Oncology Includes speakers and John Cox, Parkland Health and Hospital System/UT Southwestern Richard Friedberg, University of Massachusetts Medical School – Baystate Bruce Stewart, Massachusetts Radiological Society 10:15 am Break 1 10:30 am Session 2A: Developing and Supporting a Workforce for High-Quality Oncology Diagnosis and Care: Education and Training Moderator: James Brink, Massachusetts General Hospital
    [Show full text]
  • Maryland State Council on Cancer Control (The Council), I Am Pleased to Submit the Council’S 2018 Annual Report to You
    January 4, 2019 The Honorable Larry Hogan Governor State House Annapolis, MD 21401-1991 Dear Governor Hogan: Pursuant to Executive Order 01.01.2016.12 (2016) and on behalf of the members of the Maryland State Council on Cancer Control (the Council), I am pleased to submit the Council’s 2018 Annual Report to you. During 2018, the Council continued to carry out its mission by holding three full Council meetings and one subcommittee meeting. On November 14, 2018, the Council held the 25th Annual Maryland State Council on Cancer Control Cancer Conference. This successful event was attended by 255 people and was the direct result of the hard work and dedication of Council members and staff. In 2019, the Council will continue to use evidence-based research as the foundation for its activities and recommendations for cancer control programs and policies. The Council looks forward to continuing to build a strong relationship with your office, the Maryland Department of Health, and community organizations, so that we may all contribute in the fight against cancer in Maryland. If you have any questions regarding this report, please contact Dr. Ken Lin Tai, Director of the Center for Cancer Prevention and Control at the Maryland Department of Health, at 410-767-2036. Sincerely, Kevin Cullen, MD Chair, Maryland State Council on Cancer Control 2018 Annual Report Kevin Cullen, MD, Chair Overview and 2018 Council Activities History The Maryland State Council on Cancer Control (the Council) is a 25-member body appointed by the Governor. Members represent State agencies involved in cancer screening, prevention, and treatment services, as well as the general public, major academic medical institutions in Maryland’s cancer community, national organizations, the business community, and health and scientific disciplines concerned with cancer control.
    [Show full text]
  • Meeting Summary President's Cancer Panel The
    MEETING SUMMARY PRESIDENT’S CANCER PANEL THE FUTURE OF CANCER RESEARCH: ACCELERATING SCIENTIFIC INNOVATION September 22, 2010 Boston, Massachusetts OVERVIEW This meeting was the first in the President’s Cancer Panel’s (PCP, the Panel) 2010-2011 series, The Future of Cancer Research: Accelerating Scientific Innovation. During this meeting, the Panel heard expert testimony and moderated discussions regarding scientific progress made over the past four decades and opportunities to enhance the National Cancer Program (NCP) in coming years. The agenda for the meeting was organized into two discussion panels. PARTICIPANTS President’s Cancer Panel LaSalle D. Leffall, Jr., M.D., F.A.C.S., Chair Margaret Kripke, Ph.D. National Cancer Institute (NCI), National Institutes of Health (NIH) Abby Sandler, Ph.D., Executive Secretary, PCP Speakers John Auerbach, M.B.A., President-Elect, Association of State and Territorial Health Officials Edward J. Benz, Jr., M.D., President, Dana-Farber Cancer Institute Otis W. Brawley, M.D., Chief Medical Officer, American Cancer Society Bruce Chabner, M.D., Co-Chair, The National Cancer Advisory Board’s Ad hoc Working Group to Create a Strategic Scientific Vision for the National Cancer Program and Review of the National Cancer Institute Gwen Darien, Chair, Director’s Consumer Liaison Group, National Cancer Institute James Doroshow, M.D., Director, Division of Cancer Treatment and Diagnosis, National Cancer Institute Judy E. Garber, M.D., M.P.H., President-Elect, American Association for Cancer Research Peter Grevatt, Ph.D., Director, Office of Children's Health Protection and Environmental Education, Environmental Protection Agency William Hait, M.D., Ph.D., Senior Vice President and Worldwide Head, Ortho Biotech Oncology Research & Development, a Unit of Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
    [Show full text]
  • The Cancer Atlas 2Nd Edition (Chinese Version) Major Risk Factors of Cancer
    Symposium on Cancer Control in the Western Pacific cum Launching of Abstract: The Cancer Atlas 2nd Edition (Chinese Version) Major Risk Factors of Cancer A signicant benet of basic and epidemiologic research has been the determination of many causes of cancer. These Session II : ndings are helpful in prevention programs. The Cancer Atlas Worldwide tobacco use is the most preventable cause of cancer death. There are 1.3 billion smokers and about six million deaths occur due to smoking related cancer every year. The majority of these deaths occur in middle age. SPEAKER Tobacco use causes more than a third of all cancers. It is linked to at least twelve kinds of cancer. Among them: cancers of the lung, mouth, lip, nose and sinuses, larynx (voice box), pharynx (throat), esophagus (swallowing tube), stomach, pancreas, kidney, bladder, uterus, cervix, colon/rectum, ovary (mucinous), and myeloid leukemia. Dr. Otis BRAWLEY, MD, MACP, FASCO, FACE Chief Medical Ocer, American Cancer Society Professor of Hematology, Medical Oncology, Certain infectious agents cause cancer. The impact of infectious agents varies by region. It is estimated that infectious Medicine and Epidemiology, Emory University agents cause 33 percent of cancers in Africa, 20-26 percent in India and China, 17 percent in Southern America and 3.3 Otis Webb Brawley, MD, is an acknowledged global leader in the eld of cancer to 4 percent in North America and Australia. prevention and control. As the chief medical and scientic ocer and executive vice president of the American Cancer Society, he is responsible for promoting the goals of • Schistosomiasis (also known as bilharzia) is a at worm.
    [Show full text]
  • 2018 Highlights on Funding, Research, Education, Screening and Survivorship
    Hearts and minds working to improve cancer care in Georgia: 2018 highlights on funding, research, education, screening and survivorship Funding from the State of Georgia increased Through a contract with the Georgia Department of Public Health (GDPH), Georgia CORE received $954,000 for this fiscal year – up from $667,000 the previous year. The increase is largely a result of the advocacy work in collaboration with members of the Georgia Cancer Control Consortium (GC3). Members of the GC3 have developed funding priorities for implementation of the Georgia Cancer Plan in the fiscal year beginning July 1, 2019. Angie Patterson, Georgia CORE’s Vice President and Dr. Jim Hotz of Albany co-chair the GC3, collaborating with GDPH to develop the state’s new Comprehensive Cancer Control Plan, a roadmap for comprehensive cancer prevention and control. 6th Annual Matt Mumber Award given The Navigation Team at the Nancy N. and J.C. Lewis Cancer & Research Pavilion in Savannah won the 2018 Matt Mumber, MD, Visionary Award for Excellence in Patient Navigation. Each year at its annual meeting, the Cancer Patient Navigators of Georgia presents the award with a $2,000 grant co- sponsored by Georgia Society of Clinical Oncology (GASCO) The award was accepted by Nancy Johnson, and Georgia CORE. Kasey Wilson, and Dana Coleman. Breast Cancer License Tag grants continue to support underserved women Over the past five years, Georgia CORE has awarded $3.5 million in grants from the Breast Cancer License Tag Fund to 24 organizations. In 2018, $250,000 was awarded to eight organizations: Grady Memorial Hospital, Atlanta; Susan G.
    [Show full text]
  • Transforming the Patient Experience
    RENEW YOUR DUES TODAY! Your 2011-2012 ACE Membership renewal is just clicks away at: November 2011 cancerexecutives.org Transforming the Patient Experience By Jan Willemse, ZGF Architects LLP s we all know, living with cancer is never tunities to take back some control of their lives. easy – certainly not for the patients, not For the Brooklyn Infusion Center, MSKCC Afor their family and friends, and not for engaged ZGF Architects LLP to work on the cre- their caregivers. Most Americans will experience ation of a facility that would support a new the difficult consequences of a cancer diagnosis “chemo-ready” model of streamlined chemother- themselves or through someone they know or apy treatment. Completed in October 2010, it’s the love. Often the intense demands of treatment can first prototype center developed by MSKCC to severely disrupt daily lives and exact significant enhance the patient care experience by drastically “Completed in October 2010, it’s the first physical and psychological tolls, leaving patients reducing patient wait times and conveniently locat- prototype center developed by MSKCC and their loved ones longing for respite. ing treatment facilities in a residential neighbor- Memorial Sloan Kettering Cancer Center hood. Patients are made “chemo-ready” by per- to enhance the patient care experience” (MSKCC), the world’s oldest and largest private forming blood work and other screening proce- cancer center, is extremely active in pursuing dures the day before in MSKCC’s Manhattan facil- patients and staff within the space while utilizing treatment options and settings that optimize the ities, then provided the chemotherapy treatment full scale mockups to test the physical and psy- cancer care experience for all involved, and in on a personalized basis at the Brooklyn center.
    [Show full text]
  • Dr. Otis Brawley, the American Cancer Society November 2, 2008Welcome to Yale Cancer Center Answers with Dr
    Dr. Otis Brawley, The American Cancer Society November 2, 2008Welcome to Yale Cancer Center Answers with Dr. Ed Chu and Dr. Ken Miller. I am Bruce Barber. Dr. Chu is Deputy Director and Chief of Medical Oncology at Yale Cancer Center and Dr. Miller is a medical oncologist specializing in supportive care and he is the author of the recently published book “Choices in Breast Cancer Treatment.” If you would like to join the discussion you can contact the doctors directly at [email protected] or 1-888-234-4YCC. This evening, Dr. Ed Chu is joined by his friend Dr. Otis Brawley who is Chief Medical Officer of the American Cancer Society.Chu Let us start off by having you tell the listeners a little bit about your background and what got you interested in the whole field of oncology and cancer care.Brawley I grew up in Detroit and in high school I was very interested in science as well as politics and policy. I went to the University of Chicago, and originally was a chemistry major, met some people in the medical center and ultimately got corrupted into going into medical school. I went on to train in oncology because there were a lot of political and policy issues there. I became a practicing physician and went on to work at the National Cancer Institute for some time, and became both an administrator and a researcher there. I was recruited to Emory University as Deputy Director for Cancer Control. I spent 7 years in academia, and liked it a great deal.
    [Show full text]
  • American Cancer Society
    The American Cancer Society Guest Expert: Otis Brawley, MD Medical Director, American Cancer Society www.wnpr.org www.yalecancercenter.org Welcome to Yale Cancer Center Answers with Dr. Ed Chu and Dr. Ken Miller. I am Bruce Barber. Dr. Chu is Deputy Director and Chief of Medical Oncology at Yale Cancer Center and Dr. Miller is a medical oncologist specializing in supportive care and he is the author of the recently published book "Choices in Breast Cancer Treatment." If you would like to join the discussion you can contact the doctors directly at [email protected] or 1-888-234-4YCC. This evening, Dr. Ed Chu is joined by his friend Dr. Otis Brawley who is Chief Medical Officer of the American Cancer Society. Chu Let us start off by having you tell the listeners a little bit about your background and what got you interested in the whole field of oncology and cancer care. Brawley I grew up in Detroit and in high school I was very interested in science as well as politics and policy. I went to the University of Chicago, and originally was a chemistry major, met some people in the medical center and ultimately got corrupted into going into medical school. I went on to train in oncology because there were a lot of political and policy issues there. I became a practicing physician and went on to work at the National Cancer Institute for some time, and became both an administrator and a researcher there. I was recruited to Emory University as Deputy Director for Cancer Control.
    [Show full text]
  • Afternoon Plenary: Disparities in Cancer Survival
    Afternoon Plenary: Disparities in Cancer Survival Christopher Flowers MD, MS, FASCO • Professor of Hematology and Oncology, Winship Cancer Institute at Emory University School of Medicine • Clinical Director for Oncology Informatics Program • Director of the lymphoma program at Emory University Disparities in Cancer Survival HICOR Value in Cancer Care Summit Christopher Flowers, MD, MSc, FASCO Professor, Hematology and Medical Oncology Director, Lymphoma Program Scientific Director, Winship Research Informatics Emory School of Medicine May 13, 2019 Disclosures Consultant: Consultant: Abbvie, Astra Zeneca, Bayer, Celgene (unpaid), Denovo Biopharma, Genentech/Roche (unpaid), Gilead, OptumRx, Karyopharm, Pharmacyclics/Janssen, Spectrum Research Funding: Abbvie, Acerta, Celgene, Gilead, Genentech/Roche, Janssen Pharmaceutical, Millennium/Takeda, Pharmacyclics, TG Therapeutics, Burroughs Wellcome Fund, Eastern Cooperative Oncology Group, National Cancer Institute, V Foundation Non-Hodgkin Lymphomas • Non-Hodgkin lymphomas (NHLs) – heterogeneous group of B-cell and T-cell neoplasms – differing patterns of growth and response to treatment • Prognosis depends on histologic type, stage, and treatment SEER Cancer Statistics Review, 2015. American Cancer Society. Cancer facts and figures 2015. At: http://www.cancer.org/downloads/STT/CAFF2005f4PWSecured.pdf. Accessed December 28, 2015. Annual Lymphoid Cancers in the US U.S. cancer statistics for lymphoid malignancies by World Health Organization subtypes Teras LR, DeSantis CE, Morton LM, Cerhan JR, Jemal A, Flowers CR Survival by Gender and Race for NHL Subtypes U.S. cancer statistics for lymphoid malignancies by World Health Organization subtypes Teras LR, DeSantis CE, Morton LM, Cerhan JR, Jemal A, Flowers CR CA Cancer J Clin. 2016 Diffuse Large B-Cell Lymphoma ◼ Most common lymphoid malignancy ◼ 31% of adult NHL ◼ Aggressive: rapid growth and limited survival in the absence/inadequate tx ◼ Curable in 50% or more of cases ◼ Clinical outcomes highly variable Michallet AS, et al.
    [Show full text]